These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22782347)

  • 1. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme.
    Gill MD; Bramble MG; Rees CJ; Lee TJ; Bradburn DM; Mills SJ
    Br J Cancer; 2012 Jul; 107(3):417-21. PubMed ID: 22782347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
    George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
    Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
    Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
    Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers.
    Gill MD; Bramble MG; Hull MA; Mills SJ; Morris E; Bradburn DM; Bury Y; Parker CE; Lee TJ; Rees CJ
    Br J Cancer; 2014 Nov; 111(11):2076-81. PubMed ID: 25247322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
    Mlakar DN; Bric TK; Škrjanec AL; Krajc M
    Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
    Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
    Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of patients with symptom- and screening-detected colorectal cancer.
    Brenner H; Jansen L; Ulrich A; Chang-Claude J; Hoffmeister M
    Oncotarget; 2016 Jul; 7(28):44695-44704. PubMed ID: 27213584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal cancers detected through screening are associated with lower stages and improved survival.
    Lindebjerg J; Osler M; Bisgaard C
    Dan Med J; 2014 Jan; 61(1):A4758. PubMed ID: 24393588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study.
    Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG
    Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women.
    Blanks RG; Benson VS; Alison R; Brown A; Reeves GK; Beral V; Patnick J; Green J
    Br J Cancer; 2015 Apr; 112(9):1562-7. PubMed ID: 25742470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
    Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
    Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of ten gastrointestinal and other medical conditions with positivity to faecal occult blood testing in routine screening: a large prospective study of women in England.
    He E; Alison R; Blanks R; Pirie K; Reeves G; Ward RL; Steele R; Patnick J; Canfell K; Beral V; Green J
    Int J Epidemiol; 2019 Apr; 48(2):549-558. PubMed ID: 30668711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive impact of a faecal-based screening programme on colorectal cancer mortality risk.
    Ibáñez-Sanz G; Milà N; Vidal C; Rocamora J; Moreno V; Sanz-Pamplona R; Garcia M;
    PLoS One; 2021; 16(6):e0253369. PubMed ID: 34191813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.